Breaking News
April 24, 2018 - Study shows people might develop dementia later and live with it for a shorter period of time
April 24, 2018 - EMBL scientists develop new illumination method to manage neuropathic pain
April 24, 2018 - New compound could offer pain-relieving properties without risk of addiction
April 24, 2018 - New drug treatment could be promising therapeutic approach for millions with asthma
April 24, 2018 - Study provides guidance on using cannabis for treatment of stress, anxiety, and depression
April 24, 2018 - By Royal approval: Queen’s Award success for Elucigene
April 24, 2018 - The role of ‘extra’ DNA in cancer evolution and therapy resistance
April 24, 2018 - Researchers identify tools that caregivers could use to detect delirium in older adults
April 24, 2018 - What to Look Out For
April 24, 2018 - Drugs prescribed for newborns vary widely between NICUs, study finds
April 24, 2018 - FM4200 pressure-resistant mass flow meter from Sensirion
April 24, 2018 - Study links past experiences with bias and avoidance of doctors in women with higher BMI
April 24, 2018 - Role of extrachromosomal pieces of DNA in cancer development and treatment resistance
April 24, 2018 - Rehabilitation technique for stroke appears beneficial for multiple sclerosis patients
April 24, 2018 - Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse for Treatment of Lambert-Eaton Myasthenic Syndrome
April 24, 2018 - Suicide and homicide rates show large racial disparities across US states
April 24, 2018 - NuProbe to commercialize Wyss Institute’s new technology to facilitate precision medicine
April 24, 2018 - Special series explores pasteurized donor human milk use for hospitalized infants
April 24, 2018 - Slight changes in patient’s position during radiotherapy may impact survival chances
April 24, 2018 - FDA Approves Tagrisso (osimertinib) as First-Line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer
April 24, 2018 - After knee replacement, play on
April 24, 2018 - Contact precautions do not limit spread of drug-resistant bacteria in ICUs
April 24, 2018 - Researchers discover genetic catalysts that accelerate evolution of antibiotic resistance in bacteria
April 24, 2018 - WPI researcher launches mobile app for assessing perinatal depression in women
April 24, 2018 - Researchers identify superior blood-based biomarker for assessing sports-related concussions
April 24, 2018 - Gene Therapy Found to Be Promising for β-Thalassemia
April 24, 2018 - Bariatric surgery can lead to changes in relationship status
April 24, 2018 - GPs must embrace digital technologies to make healthcare access easier for patients
April 24, 2018 - Novel stem cell therapy may transform current paradigms for treating heart failure patients
April 24, 2018 - Maternal depression during and after pregnancy linked to poorer child neurodevelopment
April 24, 2018 - Vitamin D and magnesium supplements provide right nutritional support to athletes
April 24, 2018 - Could a Tattoo Someday Spot Your Cancer?
April 24, 2018 - Throat reflexes differ in people with tetraplegia and sleep apnea
April 24, 2018 - Study shows no increased risk of breast cancer recurrence after DIEP flap reconstruction
April 24, 2018 - Nearly three-quarters of commonly used medical scopes tainted by bacteria
April 24, 2018 - Home-based treatment program offers robust and sustained relief for IBS patients
April 24, 2018 - New IntelliCyt Cy-Clone PLUS streamlines clone ranking and selection for cell line development
April 24, 2018 - Scientists examine how specific eating patterns could help fight cancer and obesity
April 24, 2018 - Study sheds new light on how bilinguals process language
April 24, 2018 - Probiotics can improve liver health, shows study
April 24, 2018 - Study may explain how chemoresistance evolves over time in some triple-negative breast cancers
April 24, 2018 - Role of midbrain in encoding identity errors
April 23, 2018 - Salamander study provides clues for treating spinal cord injuries
April 23, 2018 - Relaxation after work could give better night’s sleep
April 23, 2018 - Loneliness on its way to becoming Britain’s most lethal condition
April 23, 2018 - Low-cost blood test for multiple myeloma can deliver same diagnostic information as bone biopsy
April 23, 2018 - Metabolic differences may contribute to postpartum weight retention in black moms
April 23, 2018 - Time-Related Deployment Factors Predict Suicide Attempt Risk
April 23, 2018 - Are newborns ugly? Research says newborns rated ‘less cute’ than older babies
April 23, 2018 - Prenatal marijuana use linked to increased chance of low birth weights
April 23, 2018 - Researchers identify target gene in P. aeruginosa infection
April 23, 2018 - New studies related to causes of liver degradation and possible treatments
April 23, 2018 - Studies offer leads for new approaches to treat neurological problems
April 23, 2018 - Promising cell study may offer new opportunities for treating Parkinson’s disease
April 23, 2018 - Gene Therapy May Be Cure for Some With Rare Blood Disorder
April 23, 2018 - Obesity impacts liver health in kids as young as eight years old
April 23, 2018 - Frequent cannabis use by young people linked to small reductions in cognitive function
April 23, 2018 - Innovative research could lead to new ways to treat, prevent cancer
April 23, 2018 - Study uncovers possible source of gender differences in migraines
April 23, 2018 - Study proves usefulness of EDX testing in diagnosis, management of neuromuscular disorders
April 23, 2018 - Hacking ‘drug trafficking’ system could increase effectiveness of diabetes treatment
April 23, 2018 - Clinical trial to examine stem cell therapy for treatment, prevention of complications after traumatic injury
April 23, 2018 - Targeted radiotherapy found to be a good option for women with early breast cancer
April 23, 2018 - Eating fish could prevent Parkinson’s disease
April 23, 2018 - Philips showcases dedicated radiation oncology solutions at ESTRO 2018
April 23, 2018 - Key factor in development of Parkinson’s disease identified
April 23, 2018 - Higher consumption of fish linked to better neurological health
April 23, 2018 - Genevac announces HT Series 3 evaporators with Inert Gas Purge option
April 23, 2018 - Researchers clarify immune response for patients with breast cancer brain metastases
April 23, 2018 - Polypharmacy More Likely for Cancer Survivors
April 23, 2018 - Obesity is shifting cancer to young adults
April 23, 2018 - Scientists illustrate role of novel chromosomal mutations in fosfomycin resistance
April 23, 2018 - Newly developed drug compound may help treat Charcot-Marie-Tooth disease
April 23, 2018 - Marriage Means ‘I Do’ for Skin Cancer Detection
April 23, 2018 - Freezing hunger-signaling nerve may help ignite weight loss
April 23, 2018 - Wear exoskeletons with caution for heavy lifting, researchers say
April 23, 2018 - Research offers new hope for healing wounds in patients with diabetes
April 23, 2018 - Shorter courses of radiotherapy found to be safe, effective for prostate cancer patients
April 23, 2018 - Scientists use CRISPR tool to make multiple edits to DNA samples ‘in vitro’
April 23, 2018 - Knee reconstructions are on the rise among the youth in Australia
Anti-PD-1 treatment reduces tumor size and post-surgical relapse of lung cancer

Anti-PD-1 treatment reduces tumor size and post-surgical relapse of lung cancer

image_pdfDownload PDFimage_print

A drug given to early stage lung cancer patients before they undergo surgery showed major tumor responses in the removed tumor and an increase in anti-tumor T-cells that remained after the tumor was removed, which resulted in fewer relapse cases in the patients.

The research teams at the Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, the Johns Hopkins Sidney Kimmel Cancer Center and the Memorial Sloan-Kettering Cancer Center wanted to find out if providing nivolumab, an anti-PD-1 drug, would stimulate anti-tumor immunity in patients with non-small-cell lung cancer (NSCLC) who were going to have their tumors surgically removed.

The study showed after 21 patients received two doses of nivolumab before surgery, there was a major pathologic response in 45 percent of the removed tumors and no delays in any of the planned surgeries. In addition, neoantigen-specific T-cell clones were stimulated by the drug and present in the blood and tumor but disappeared from the body after the tumor was removed.

The study was published in the New England Journal of Medicine on April 16, 2018.

“We wanted to look at the patients’ tumor and immune system prior to treatment and examine it again after treatment for changes,” said Patrick Forde, M.B.B.Ch., first author and co-principle investigator of the trial and a lung cancer oncologist in the Bloomberg~Kimmel Institute of Cancer Immunotherapy. “We found tumor regression in almost half of these early stage lung cancer patients. We weren’t expecting to see major pathology with only two doses (of nivolumab).”

Forde said the number of gene mutations in the tumor correlated closely with response to treatment and was a potential predictive marker for future studies. The research teams discovered new infiltration of immune cells into the lung cancer after the drug was administered.

“Given that phase 3 clinical trials are underway, using this neoadjuvant anti-PD-1 drug will likely be practice changing,” said Drew Pardoll, M.D., Ph.D., senior author, director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and co-director of the Cancer Immunology Program at the Kimmel Cancer Center.

“There was a major pathological response in almost half the patients, the tumor was almost totally overrun by lymphocytes at the time of resection, and we were able to demonstrate using a new assay we developed that tumor-specific T-cells spilled out into the blood after treatment.”

Twenty-one patients enrolled in the study were 18 years of age and older and had stage I, II or IIIA NSCLC that was deemed resectable. Twenty of the 21 received 3 mg/kg of nivolumab intravenously every two weeks for two doses prior to surgery. One patient underwent an uncomplicated surgery after only one dose.

Twenty patients underwent complete tumor resection after receiving the drug. Upon follow-up after surgery, 16 of the 20 patients were alive and recurrence-free. One patient without recurrence died from a traumatic head injury unrelated to the study.

Three patients experienced tumor relapse. Two of the patients underwent further treatment and have not had further recurrence. One patient died of relapsed metastatic cancer about 16 months after surgical resection.

Pardoll said historically, approximately 50 percent of NSCLC patients who undergo surgery will relapse. Chemotherapy can add about 5 percent to survival but introduces toxicity to surrounding tissue. The results from the study showed neoadjuvant anti-PD-1 treatment could enhance the priming of anti-tumor T-cells, potentially eliminating micro-metastatic cancer that can cause post-surgical relapse.

“That T-cells, activated by immunotherapy prior to surgery, can intercept rogue tumor cells throughout the body after the patient’s operation and prevent the cancer from recurring may be a game-changer. This notion of ‘cancer interception’ has the potential to stop cancer in its tracks, helping turn cancer patients into long-term survivors, and it is a significant focus for (Stand Up To Cancer). We look forward to learning the results of the follow-up clinical studies that are underway to see how this breakthrough benefits a larger number of patients,” said Stand Up To Cancer President and CEO Sung Poblete, Ph.D., RN.

Larger studies are needed to examine the effects of combination immunotherapies, longer courses of a neoadjuvant drug and to define the role of the anti-PD-1 in reducing recurrences and curing early stage cancers.

“The potential to transform treatment of lung cancer patients resulting from this groundbreaking work by Forde, Pardoll, and other members of the SU2C-CRI Immunology Dream Team demonstrates the power of cross-disciplinary collaboration to advance lifesaving translational research, where the laboratory and clinic meet, and underscores the importance of continued efforts to explore fully immunotherapy’s promise at various stages of treatment along the entire patient journey,” said Jill O’Donnell-Tormey, Ph.D., CEO and director of scientific affairs at the Cancer Research Institute.

Source:

http://www.hopkinsmedicine.org/

Tagged with:

About author

Related Articles